By Kosaku Narioka

Takeda Pharmaceutical is scheduled to report its third-quarter results on Thursday. Here's what you need to know:

NET PROFIT FORECAST: Takeda's net profit is expected to have more than quadrupled to 107.9 billion yen, equivalent to $708.9 million, for the three months ended December, according to a poll of analysts by Visible Alpha. The company reported net profit of Y23.8 billion in the year-earlier period, which was weighed by restructuring expenses.

REVENUE FORECAST: Third-quarter revenue is estimated to have increased 4.0% from a year earlier to Y1.190 trillion, according to the Visible Alpha poll.

The stock has risen 6.1% year to date through Tuesday, following a 16% increase in 2025.

WHAT TO WATCH:

--For the fiscal year ending March, Takeda projected revenue to decline 1.8% to Y4.500 trillion and net profit to increase 42% to Y153.00 billion. Investors will be closely watching any changes to annual guidance that management may make.

--Second-quarter sales of plasma-derived products fell 2.9% to Y256.6 billion while sales of ulcerative colitis drug Entyvio climbed 3.3% to Y246.7 billion. Investors will be focusing on sales momentum of its key products.

--The company's operating profit margin deteriorated to 6.2% in its second quarter from 15.7% in the year-earlier period. Investors will be paying attention to margin trends as businesses are dealing with relatively high inflation in many parts of the world.

Write to Kosaku Narioka at kosaku.narioka@wsj.com

(END) Dow Jones Newswires

January 28, 2026 00:41 ET (05:41 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.